Eton Pharmaceuticals vs Xeris Biopharma
ETON and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ETON and XERS compare
Xeris Biopharma is the larger company, worth 1.7 times as much as Eton Pharmaceuticals ($3.1B against $1.8B).
Eton Pharmaceuticals grew revenue faster over the last twelve months (81.5% versus 36.3% for Xeris Biopharma).
Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 12.0% compared with −5.1% at Xeris Biopharma.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ETON | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $3.1B |
| Share price | $63.65 | $16.80 |
| Change, 1 year | 276% | 134% |
| Change, 5 years | 1408% | 674% |
| Beta (5Y) | −0.44 | 0.27 |
| Employees | 44 | 435 |
| StockData Score | ||
| Total score | 10 | 10 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 163× | – |
| P/S | 17.2× | 9.1× (better) |
| P/B | 39.1× | – |
| EV/EBITDA | 87.3× | 84.2× (better) |
| P/FCF | 123× | – |
| FCF yield | 0.81% | – |
| Fair value | $10.20 | – |
| Margin of safety | −524% | – |
| Growth | ||
| Revenue growth (TTM) | 81.5% (better) | 36.3% |
| Revenue growth, 5Y average | 360% (better) | 70.2% |
| Profitability | ||
| Gross margin | 57.9% | 86.6% (better) |
| Operating margin | 15.4% (better) | 10.9% |
| Net margin | 12.0% (better) | −5.1% |
| FCF margin | 14.0% | – |
| Return on equity | 36.0% | – |
| Return on invested capital | 42.5% (better) | 22.1% |
| Financial health | ||
| Debt / equity | 0.60 | – |
| Net debt / EBITDA | 0.05 (better) | 3.45 |
| Interest coverage | 3.6× (better) | 1.3× |
| Current ratio | 1.52 (better) | 1.45 |
| Altman Z-score | 16.19 (better) | 3.33 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 74.0% | 59.4% |
| Held by insiders | 5.6% | 5.2% |
| Insider net buying, 12 months | −$35.0M | −$5.8M (better) |
| Short interest, % of float | 7.4% | 5.2% |
Go deeper
- ETON stock overview
- ETON income statement
- ETON valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.